InnoCare Included in the MSCI China All Share Small Cap Index

Beijing, Dec. 1, 2023——InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company has been included in the MSCI (Morgan Stanley Capital Index) China All Share Small Cap Index with effect from November 30, 2023 after the close of the market Hong Kong time.

This reflects the recognition of the Company's corporate value, innovation strength, and future potential by the leading international index provider MSCI capital market, which will further enhance the Company's influence in international and domestic capital markets.

The MSCI Index, launched by Morgan Stanley Capital International, is the most influential stock index in the world, the most commonly used benchmark index by global portfolio managers, and the primary index referenced by over 90% of institutional investors worldwide.

The MSCI China Index is one of the indices under the MSCI system, and includes companies that have representative, good business operations and strong growth potential.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.